- Conditions
- Other Infectious Diseases
- Interventions
- Cefepime, Ceftolozane, Laboratory Biomarker Analysis, Meropenem, Piperacillin-Tazobactam, Tazobactam
- Drug · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Houston, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 52
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Complicated Intra-abdominal Infections, Complicated Appendicitis
- Interventions
- Eravacycline, Meropenem, Placebo
- Drug
- Lead sponsor
- Tetraphase Pharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Indianapolis, Indiana • Las Vegas, Nevada + 3 more
- Conditions
- Cystic Fibrosis, Chronic Bronchitis
- Interventions
- IV amikacin, PO azithromycin, IV ceftazidime, PO ciprofloxacin, IV meropenem, IV piperacillin-tazobactam, IV ticarcillin-clavulanate, IV tobramycin
- Drug
- Lead sponsor
- Seattle Children's Hospital
- Other
- Eligibility
- 14 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 8
- States / cities
- Iowa City, Iowa • St Louis, Missouri • Cincinnati, Ohio + 4 more
- Conditions
- Pancreatitis, Acute Necrotizing
- Interventions
- meropenem
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2004
- U.S. locations
- 9
- States / cities
- San Francisco, California • Tampa, Florida • Chicago, Illinois + 6 more
- Conditions
- Healthcare-associated Pneumonia (HCAP), Hospital Acquired Pneumonia (HAP), Ventilator Associated Pneumonia (VAP)
- Interventions
- Cefiderocol, Meropenem, Linezolid
- Drug
- Lead sponsor
- Shionogi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 15
- States / cities
- New Haven, Connecticut • DeLand, Florida • Chicago, Illinois + 12 more
- Conditions
- Pneumonia
- Interventions
- MERREM I.V. 2g as a 3 hour infusion every 8 hours, vancomycin I.V. 1 g every 12 hours, tobramycin I.V. 5 mg/kg every 24 hours, MERREM I.V. 1g as a 30 minute infusion every 8 hours, MERREM I.V. 500 mg as a 3 hour infusion every 8 hours
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2004
- U.S. locations
- 10
- States / cities
- Phoenix, Arizona • Newark, Delaware • Indianapolis, Indiana + 7 more
- Conditions
- Pneumonia
- Interventions
- Murepavadin, Two anti-pseudomonal antibiotics
- Drug
- Lead sponsor
- Polyphor Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • Springfield, Missouri • Greensboro, North Carolina
- Conditions
- Necrotizing Enterocolitis, Intra-abdominal Infection
- Interventions
- meropenem
- Drug
- Lead sponsor
- The Emmes Company, LLC
- Industry
- Eligibility
- Up to 90 Days
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 26
- States / cities
- Birmingham, Alabama • Oakland, California • Orange, California + 21 more
- Conditions
- Bacterial Infections
- Interventions
- Vabomere
- Drug
- Lead sponsor
- Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC)
- Industry
- Eligibility
- Up to 17 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2026
- U.S. locations
- 9
- States / cities
- Little Rock, Arkansas • Los Angeles, California • Orange, California + 6 more
- Conditions
- Healthy Volunteers
- Interventions
- RO7079901, Meropenem, RO7049389 Placebo, Meropenem Placebo
- Drug · Other
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 2
- States / cities
- Evansville, Indiana • Madison, Wisconsin
- Conditions
- Bacterial Infections
- Interventions
- KSP-1007, Placebo:0.9% sodium chloride, Meropenem
- Drug · Other
- Lead sponsor
- Sumitovant Biopharma, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 123 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Lenexa, Kansas
- Conditions
- Complicated Intra-abdominal Infection
- Interventions
- CXA-101/ tazobactam and metronidazole, meropenem plus saline placebo
- Drug
- Lead sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 122 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 11
- States / cities
- Orange, California • Torrance, California • Aurora, Colorado + 8 more
- Conditions
- Pharmacokinetics Study on Healthy Volunteers Adults
- Interventions
- ANT3310, Meropenem
- Drug
- Lead sponsor
- Antabio
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Pneumonia
- Interventions
- Murepavadin, One anti-pseudomonal antibiotic
- Drug
- Lead sponsor
- Polyphor Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 2
- States / cities
- Iowa City, Iowa • Pittsburgh, Pennsylvania
- Conditions
- Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children, Hypertension, Pain, Hyperphosphatemia, Primary Hyperaldosteronism, Edema, Hypokalemia, Heart Failure, Hemophilia, Menorrhagia, Insomnia, Pneumonia, Skin Infection, Arrythmia, Asthma in Children, Bronchopulmonary Dysplasia, Adrenal Insufficiency, Fibrinolysis; Hemorrhage, Attention Deficit Hyperactivity Disorder, Multisystem Inflammatory Syndrome in Children (MIS-C), Kawasaki Disease, Coagulation Disorder, Down Syndrome
- Interventions
- The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 0 Years to 20 Years
- Enrollment
- 5,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2026
- U.S. locations
- 49
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 40 more
- Conditions
- Pneumonia, Blood Stream Infection
- Interventions
- colistin and meropenem, colistin and placebo
- Drug
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 18 Years to 95 Years
- Enrollment
- 467 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2020
- U.S. locations
- 6
- States / cities
- Miami, Florida • Detroit, Michigan • Royal Oak, Michigan + 2 more
- Conditions
- Complicated Urinary Tract Infection, Pyelonephritis
- Interventions
- Ceftolozane/Tazobactam, Meropenem
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 7 Days to 17 Years
- Enrollment
- 134 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Orange, California • San Diego, California + 6 more
- Conditions
- Gram-negative Bacteremia
- Interventions
- Intravenous Antibiotics, Oral Antibiotics
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,030 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 11
- States / cities
- San Francisco, California • Denver, Colorado • Baltimore, Maryland + 7 more
- Conditions
- Bacterial Pneumonia
- Interventions
- IV meropenem, I.V. Meropenem, Parenteral aminoglycoside; tobramycin for injection USP OR gentamicin sulfate injection solution concentrate 5mg.kg IV q24h; amikacin sulfate injection USP 20 mg/kg IV q24h, Linezolid or Vancomycin (per institutional guidelines) will be available for MRSA coverage., tobramycin nebulization
- Drug · Device
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 8
- States / cities
- San Mateo, California • Gainesville, Florida • Atlanta, Georgia + 5 more
- Conditions
- Abscess, Intra-Abdominal, Abdominal Abscess, Abdomen, Acute, Abdominal Pain, Appendicitis, Rupture, Infection, Intestinal Perforation, Peritonitis, Ileus
- Interventions
- Doripenem, Meropenem placebo, Meropenem, Doripenem placebo, Amoxicillin/clavulanate potassium
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 3 Months to 18 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 4
- States / cities
- San Diego, California • Washington D.C., District of Columbia • Cleveland, Ohio + 1 more
- Conditions
- Complicated Intra-abdominal Infection
- Interventions
- CXA-201 and metronidazole, Meropenem
- Drug
- Lead sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 494 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 4
- States / cities
- Springfield, Illinois • Boston, Massachusetts • Robbinsdale, Minnesota + 1 more
- Conditions
- Complicated Intra-abdominal Infection, Hosptial Acquired Pneumonia, Ventilator Associated Pneumonia
- Interventions
- ATM-AVI, MTZ, MER, COL
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 422 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 5
- States / cities
- Tucson, Arizona • Torrance, California • Springfield, Illinois
- Conditions
- Acute Pyelonephritis, Complicated Urinary Tract Infection
- Interventions
- Meropenem-Vaborbactam, Antibiotics
- Drug
- Lead sponsor
- Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC)
- Industry
- Eligibility
- 3 Months to 11 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 4
- States / cities
- Little Rock, Arkansas • Orange, California • Omaha, Nebraska + 1 more
- Conditions
- Complicated Intra-abdominal Infections
- Interventions
- Ceftazidime -avibactam, Meropenem, Metronidazole
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 3 Months to 17 Years
- Enrollment
- 83 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 4
- States / cities
- Orange, California • San Diego, California • Toledo, Ohio + 1 more